Rationally Engineered Proteins or Antibodies with Absent or Reduced Immunogenicity

Author(s):

S. Tangri, C. LiCalsi, J. Sidney and A. Sette   Pages 2191 - 2199 ( 9 )

Abstract:

One challenge associated with the clinical use of protein therapeutics destined for chronic administration is the potential for the development of unwanted anti-drug immune reactions. The molecular basis for this reactivity is the binding of peptide fragments (epitopes) derived from the breakdown of the

Keywords:

epitope,immunostealth,antibody,htl

Affiliation:

, , , Epimmune Incorporated, 5820 Nancy Ridge Drive, San Diego, CA-92121, USA

Read Full-Text article